ClinicalTrials.gg
RecruitingNCT07340671Updated Jul 24, 2026

Facial Papules in Frontal Fibrosing Alopecia (FFA)

An interventional study of Cutera® 1726 nm laser system in Frontal Fibrosing Alopecia, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by University of Miami · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
174th of 204
10 · median 40
Started
2026
with 14 others
No phase
93 of 217
24 open now
Primary completion
2027-04
later than 36 of 62 live
Registered
202nd of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 174th largest by planned enrollment of the 204 interventional ones that give a count, is one of 15 that started in 2026, is one of 93 with no phase, reaches primary completion later than 36 of the 62 other live ones, and was the 202nd registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

The objective is to evaluate the safety and efficacy of the Cutera 1726 nm laser system (also referred to as AviClear) for the treatment of facial papules in frontal fibrosing alopecia (FFA).

03

Conditions studied

  • Frontal Fibrosing Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or Male
  • Fitzpatrick Skin Types I-VI
  • At least 18 years of age
  • Has clinically diagnosed FFA with facial papules.
  • Subject must be able to read, speak, and understand English or Spanish and sign the Form.
  • Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions.
  • No to laser therapy.
  • Willing to have photographs taken of the treatment area and agree to the use of photographs for presentation, educational or marketing purposes.
  • Agree to not undergo any other procedure(s) or add any new treatment modalities in the treatment area during the study.
  • Willing to use investigator approved skincare topicals and follow investigator approved skincare regimen for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.
  • Prior treatment to the target area within 3 months of study participating including chemical peel, dermabrassion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional , photodynamic therapy, or acne surgery.
  • Prior injection of botulinum toxin in the target area within 3 months of study participation and for the duration of the study.
  • Systemic use of retinoid, such as isotretinoin, within 3 months of study participation.
  • Still healing from another treatment in the target area according to investigator's discretion.
  • History of malignant tumors in the target area.
  • Pregnant and/or breastfeeding or planning to become pregnant during the study.
  • History of diagnosed /immune deficiency or currently using immunosuppressive medications.
  • History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.
  • Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
  • History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen.
  • History of radiation to the target area, currently undergoing treatment for skin cancer in the target area, or undergoing systemic chemotherapy for the treatment of cancer.
  • History of diagnosed pigmentary disorders (including vitiligo) in the target area.
  • Excessively tanned in the treatment area or unable/unlikely to refrain from tanning in the target area during the study.
  • History of keloids or hypertrophic scarring.
  • Prisoners
  • As per the Investigator's discretion, any physical, mental or medical condition which might make it unsafe for the subject to participate in this study, might interfere with patient's participation in the full study protocol, or might interfere with the diagnosis or assessment of facial papules.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    1726 nm Laser Treatment Group

    Participants will be in this group for up to approximately 30 weeks and complete up to 5 visits

    Device: Cutera® 1726 nm laser system

Interventions

  • DeviceCutera® 1726 nm laser system

    Participants will receive 3 laser treatments at 4 (±1) week intervals and will be followed at approximately at 12 (± 2) weeks post treatment completion onsite.

    Also known as: Cutera®, AviClear®

06

What researchers measure

Primary outcomes

  1. Change in lesion size (papule diameter in mm) measured by dermatoscope and ultrasound

    Lesion size will be assessed using dermatoscope and ultrasound imaging. Measurements will be recorded in millimeters (mm) and compared to baseline values to evaluate treatment response.

    Time frame: Baseline periprocedural and through study completion (an average of 30 weeks)

Secondary outcomes

  1. Change in lesion count measured by physical examination

    Lesions will be counted manually during physical examination at each time point. Counts will be compared to baseline to assess treatment response

    Time frame: Baseline periprocedural and through study completion (an average of 30 weeks)

  2. Change in lesion depth measured by optical coherence tomography (OCT) and/or ultrasound

    Using optical coherence tomography (OCT) and/or ultrasound to measure subsurface changes, including lesion depth and size. Measurements will be compared to baseline to evaluate treatment response.

    Time frame: Baseline, periprocedural, and through study completion (an average of 30 weeks)

  3. Change in appearance of facial papules assessed by standardized global photography

    Facial papule appearance will be documented using standardized global photographs at each time point. Images will be evaluated for visual changes compared to baseline.

    Time frame: Baseline, periprocedural and through study completion (an average of 30 weeks)

  4. Change in Physician Global Assessment (PGA) score (9-point ordinal scale)

    A board-certified physician will evaluate overall lesion severity using a standardized 9-point ordinal scale. Scores range from 0-8, with higher scores indicate greater severity. Scores at follow-up will be compared to baseline to assess treatment response.

    Time frame: Baseline and through study completion (an average of 30 weeks)

  5. Blinded dermatologist evaluation

    Before and after photos will be provided to three blinded dermatologists. Dermatologists will be asked to identify the correct before and after photos. Correct identification greater than or equal to 80% percent of the time is considered statistically significant.

    Time frame: After data collection is completed (an average of 30 weeks from baseline)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's planned 11 months is below that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Jan 14, 2026
StartActual
Apr 28, 2026
Primary completionEst.
Apr 26, 2027
CompletionEst.
Apr 28, 2027
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07340671
Collaborators
Cutera Inc.
Responsible party
Ariel Eva Eber (Assistant Professor of Clinical, University of Miami) — Principal investigator
First posted
Jan 14, 2026
Start date
Apr 28, 2026
Primary completion
Apr 26, 2027 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Jul 24, 2026

Study contacts

Maria V Muniz
Contact
mmuniz@med.miami.edu
305-689-2646
Leigh Nattkemper, PhD
Contact
lxn202@med.miami.edu
305-588-9734

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion